Company
Novartis AG (ADR)
NYSE:NVS
Novartis provides healthcare solutions that address the evolving needs of patients and societies.
44 stories
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR...
Dow closes sharply lower as oil surge fuels inflation fears
4:15pm: Oil spike hits stocks US stocks closed sharply lower on Tuesday as surging oil prices revived inflation worries and pushed investors to reassess the...
Novartis to axe 8,000 jobs, some will be transferred to India
Vas Narasimhan, the company's chief executive projected job cuts in the "single-digit thousands" as part of a restructuring programme announced in April, aiming to save US$1bn by 2024
Tarus Therapeutics beefs up its board of directors with a pair of pharmaceutical industry veterans
The firm added David Epstein, the former CEO of Novarits Pharmaceuticals, and David Nicholson, who has served in leadership roles at Allergan, Bayer CropScience and elsewhere
Aequus Pharma’s sales push expands market for revenue-drivers Tacrolimus and Vistitan
CEO Doug Janzen says the long-term revenue potential for both drugs remains high after final royalty adjustments with Sandoz
Investments and investor services
IPO Roundup: Rattler Midstream holds steady after its debut; Bicycle Therapeutics off to a wobbly start
Two cancer biotechnology companies made their debuts along with a Texas oil company
Investments and investor services
IPO Roundup: Peloton Therapeutics gobbled up by Merck just as it prepared to go public
The sale provides Peloton shareholders with $1.05 billion in cash, with a possible $1.15 more if its treatments hit certain milestones
Investments and investor services
IPO Roundup: Peloton Therapeutics, Rattler Midstream headline the week's slate of public offerings
Three biopharmaceutical companies are going public with one Texas oil company thrown in the mix
Investments and investor services
LATE MOVERS: Cerner rises on cooperation agreement with activist hedge fund; Boeing's 737 deliveries drop
Also making moves on Tuesday were Novartis, United States Steel, Zogenix and Kodak
CryptoCann™ Report: Western Union may add crypto services; Missouri takes a step forward in licensing medical marijuana businesses
Missouri is expected to generate between $175 million to $275 million in annual marijuana sales, as per Marijuana Business Daily data
Conatus Pharmaceuticals shares tank after missing primary endpoint in clinical trial of its liver disease drug
Results from the Phase 2b clinical trial of liver disease drug Emriscan failed to show a meaningful difference when compared with the placebo
Investments and investor services
Canadian cannabis company Tilray rated a Buy with a price target of $200 by Benchmark analyst
The global cannabis market opportunity could top $200 billion over the long term and the companies Benchmark is recommending are ideally positioned to take advantage
Hardware & electrical equipment
Tilray CEO encourages pharma and booze companies to enter the cannabis space; shares soar
CEO Brendan Kennedy tells CNBC's Jim Cramer that the cannabis space is potentially worth US$150bn
Tilray to export medical cannabis flower to Germany
The Canadian cannabis group has received the required permits from Germany and Canada to sell whole flower cannabis products in Germany
Tilray shares finish lower after downgrade by Northland Capital Markets
The downgrade came as Tilray secured another supply agreement, ahead of Canada’s legalization of recreational cannabis next month
Immutep valuation increased 16% to $510 million by Edison Investment Research
The research note puts the value per share at 14 cents each, or 12 cents after dilutions.
Merck milestone payment helps Aduro Biotech to beat analyst estimates with 1Q results
Oppenheimer says company's cash position 'should continue to provide operational freedom'
Archive
International Business Machines, General Mills, Alibaba Group - PRE-MARKET
Proactive picks out some highlight stocks from Wednesday's pre-market trade
Cerulean Pharma shares soar after news of Novartis tie-up
The struggling microcap has signed a discovery and development deal with a giant of the pharmaceutical industry
Wednesday’s trending – Apple, oil and biotech
There were some big names taking a hit on Wednesday shedding light on the state of the global economy and none bigger than Apple...
US Risers & Fallers: Zafgen, GenVec, TASER, Kingtone, Turtle Beach, Valmie Resources
Below are some of the main news-driven share price changes as at 2:40 p.m. in New York.
GenVec awaits guidance from Novartis after study pause
GenVec says Novartis will continue to collect safety data on the nine patients currently enrolled in the study before determining whether to proceed with incremental patients.
Wall Street tumbles as China equities plunge stokes global growth worries
Wall Street lost more than 1 percent before the close today as market turmoil in China overshadowed Greece's debt crisis, while trading on the New York Stock Exchange resumed after a three-hour halt. The S&P 500 (INDEXSP:.INX) sank 1.5
Novartis' breakthrough Entresto receives FDA approval ahead of schedule
The new drug is likely to be very popular in the market and a consensus of Thomson-Reuters sector analysts expect annual sales of US$4.4 billion by 2020
Wall Street extends rout on growing Greek default fears
Wall Street stretched its losses in heavy trading today after a collapse in Greek bailout talks raised fears that the country could be the first to exit the euro zone. The S&P 500 (INDEXSP:.INX) skidded 2 percent to 2,058.63 at 3:45 p.m
U.S. stock futures tumble as Greek debt crisis deteriorates
U.S. stock-index futures dropped 1 percent today on growing concern that Greece will leave the euro region after bailout talks with lenders broke down over the weekend. Futures for Dow Jones Industrial Average tumbled 1 percent to 17,700, w